Laekna (HKSE:02105) EPS (Basic) : HK$-0.76 (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Laekna EPS (Basic)?

Laekna's basic earnings per share (Basic EPS) for the six months ended in Dec. 2024 was HK$-0.33. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.76.

Laekna's EPS (Diluted) for the six months ended in Dec. 2024 was HK$-0.33. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.76.

Laekna's EPS without NRI for the six months ended in Dec. 2024 was HK$-0.33. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.76.

During the past 3 years, the average EPS without NRI Growth Rate was -2.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Laekna's highest 3-Year average EPS without NRI Growth Rate was -2.20% per year. The lowest was -2.20% per year. And the median was -2.20% per year.

Laekna EPS (Basic) Historical Data

The historical data trend for Laekna's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna EPS (Basic) Chart

Laekna Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

-2.35

-22.37

-1.84

-0.76

Laekna Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EPS (Basic)	Get a 7-Day Free Trial			-13.73	-2.88	-0.43	-0.43	-0.33

Laekna EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Laekna's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-271.505	-	0)	/	357.626
	=	-0.76

Laekna's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-118.074	-	0)	/	359.271
	=	-0.33

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.76

Laekna (HKSE:02105) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Laekna EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Laekna's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Laekna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

4U4:Germany

Address

No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203

Website

https://www.laekna.com

Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.

Executives

Orbimed Advisors Iii Limited	2102 Investment manager
Orbimed Asia Gp Iii, L.p.	2102 Investment manager
Orbimed Asia Partners Iii, L.p.	2102 Investment manager
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo	2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si	2101 Beneficial owner
Laekna Wonderland Limited	2101 Beneficial owner
Lu Chris Xiangyang	2501 Other
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Gp Healthcare Capital, Inc.	2101 Beneficial owner
Liu Zeng	2201 Interest of corporation controlled by you
Ealex Llc	2101 Beneficial owner
Futu Trustee Limited	2301 Trustee

Laekna Headlines

No Headlines